| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 52 nM (calmodulin-dependent protein kinase II)[1].
Calmodulin-Dependent Protein Kinase II (290-309) acetate targets Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) by binding to the autoinhibitory domain and preventing kinase activation. It is a potent antagonist with an IC50 of 52 nM for inhibition of CaMKII. |
|---|---|
| ln Vitro |
It has been discovered that peptides 290 to 309 are strong calmodulin antagonists, inhibiting Ca2+/calmodulin-dependent protein kinase with an IC50 of 52 nM. Calmodulin binding is not significantly affected by truncation from the amino terminus (peptide 296-309) or extension in the carboxyl-terminal direction (peptide 294-319). However, this activity is eliminated by shortening the peptide from the carboxyl terminus (peptide 290-302) or from both ends (peptide 295-304)[1].
In vitro, Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca²⁺/calmodulin-dependent protein kinase II. It is used to study the role of CaMKII in various cellular processes. |
| ln Vivo |
Specific in vivo activity data for Calmodulin-Dependent Protein Kinase II (290-309) acetate are not detailed in available sources. As a potent CaMKII antagonist, it may have potential for in vivo studies of synaptic plasticity, learning and memory, and other CaMKII-dependent processes.
|
| Enzyme Assay |
Non-cellular enzyme assays for Calmodulin-Dependent Protein Kinase II (290-309) acetate involve measuring its inhibitory activity against purified CaMKII. The compound is incubated with the enzyme, calmodulin, Ca²⁺, and a peptide substrate, and the inhibition of kinase activity is quantified to determine the IC50 value.
|
| Cell Assay |
In vitro cellular assays for Calmodulin-Dependent Protein Kinase II (290-309) acetate are performed using cells to assess its effects on CaMKII activity. Cells are treated with the peptide, and CaMKII-mediated phosphorylation of substrates is measured by Western blotting using phospho-specific antibodies.
|
| Animal Protocol |
In vivo animal experiments for Calmodulin-Dependent Protein Kinase II (290-309) acetate would typically be conducted in animal models of synaptic plasticity or learning and memory. The compound would be administered via appropriate routes, and endpoints would include assessment of CaMKII activity and behavioral outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for Calmodulin-Dependent Protein Kinase II (290-309) acetate are not detailed in available sources. It is a peptide corresponding to residues 290-309 of CaMKII and is supplied as an acetate salt for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicological data for Calmodulin-Dependent Protein Kinase II (290-309) acetate are not provided in available sources. As a research peptide, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM. It is used in research on calcium signaling, synaptic plasticity, and autophagy. No clinical trial or regulatory approval information is available.
|
| Molecular Formula |
C105H189N31O26S
|
|---|---|
| Molecular Weight |
2333.88
|
| Related CAS # |
Calmodulin-Dependent Protein Kinase II (290-309);115044-69-4
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4285 mL | 2.1424 mL | 4.2847 mL | |
| 5 mM | 0.0857 mL | 0.4285 mL | 0.8569 mL | |
| 10 mM | 0.0428 mL | 0.2142 mL | 0.4285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
